Cytogen, Inc. Share Price

Equities

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. 03:30:00 31/05/2024 am IST 5-day change 1st Jan Change
9,810 KRW -1.51% Intraday chart for Cytogen, Inc. +5.48% -27.44%

Financials

Sales 2022 76Cr 6L 4.59Cr Sales 2023 318.44Cr 23.05L 19Cr Capitalization 26TCr 19Cr 1.55TCr
Net income 2022 -1.88TCr -1.36Cr -113.29Cr Net income 2023 -1.58TCr -1.14Cr -95Cr EV / Sales 2022 392 x
Net Debt 2022 850.24Cr 61.56L 51Cr Net cash position 2023 3.73TCr 2.7Cr 225.18Cr EV / Sales 2023 69.1 x
P/E ratio 2022
-15.2 x
P/E ratio 2023
-15.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 60.03%
More Fundamentals * Assessed data
Dynamic Chart
Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors CI
Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors CI
Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited CI
Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited CI
Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion CI
Cytogen, Inc. announces tranche update CI
Cytogen Raising KRW10 Billion to Finance Operations MT
Cytogen, Inc. announced that it expects to receive KRW 69.99999 billion in funding from Excelsior Capital Korea Limited CI
Cytogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Cytogen, Inc.(KOSDAQ:A217330) added to S&P Global BMI Index CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc. CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc. CI
Cytogen, Inc. announced that it has received KRW 30 billion in funding CI
Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding CI
TSD Life Sciences Co.,Ltd. announced that it expects to receive KRW 2.9999853 billion in funding from Cytogen, Inc. CI
More news
1 day-1.51%
1 week+5.48%
1 month-21.46%
3 months-29.32%
6 months-26.74%
Current year-27.44%
More quotes
1 week
8 620.00
Extreme 8620
11 700.00
1 month
8 620.00
Extreme 8620
12 170.00
Current year
8 620.00
Extreme 8620
16 640.00
1 year
8 620.00
Extreme 8620
19 330.00
3 years
8 620.00
Extreme 8620
24 166.67
5 years
2 266.67
Extreme 2266.6667
24 166.67
10 years
2 266.67
Extreme 2266.6667
24 166.67
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 -
Comptroller/Controller/Auditor 62 -
Members of the board TitleAgeSince
Chief Executive Officer 65 -
Director/Board Member 55 -
Director/Board Member 56 -
More insiders
Date Price Change Volume
31/24/31 9,810 -1.51% 58,101
30/24/30 9,960 +0.10% 61,387
29/24/29 9,950 -0.90% 94,214
28/24/28 10,040 +11.18% 436,547
27/24/27 9,030 -2.90% 59,623

End-of-day quote Korea S.E., May 31, 2024

More quotes
Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A217330 Stock